A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025
in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of
systemic therapy

Inclusion Criteria:

1. Male and female subjects at least 12 years of age who have had allogenic hematopoietic
cell transplant (HCT).

2. Previously received at least 2 and not more than 5 lines of systemic therapy for cGVHD

3. Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to
screening

4. Have persistent cGVHD manifestations and systemic therapy is indicated

5. Karnofsky Performance Score of ≥ 60 (if aged 16 years or older); Lansky Performance
Score of ≥ 60 (if aged < 16 years)

6. Weight ≥ 40kg

Exclusion Criteria:

1. Subjects has not been on a stable dose / regimen of systemic cGVHD treatments for at
least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin
inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis
(ECP) are acceptable. Systemic investigational GVHD treatments are not permitted).

2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative
disease at the time of screening.

3. Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a
washout of at least 28 days prior to randomization.